JB Pharma sets Asia Book of Record for Most Number of Microalbuminuria Tests (MICRAL) conducted for Hypertension Patients in India

• The company conducted over 17000+ microalbuminuria tests within a single week to achieve this Asia Book Record
• Findings from these Microalbuminuria Tests Uncovered 67.04% of the hypertensive patients tested, showing early signs of potential kidney damage

JB Pharma is making significant strides in the fight against hypertension and its impact on kidney health, in India. On the occasion of the upcoming ‘World Hypertension Day’ celebrated on 17th May, the company today, announced that it has been recognized by the Asia Book of Records for conducting a remarkable 17,202 microalbuminuria tests within a single week. This achievement is a part of JB’s ongoing “One Mission, Nephro Protection” campaign, focused on raising awareness about early detection of kidney damage in hypertensive patients.

“Achieving this recognition from the Asia Book of Records for conducting the highest number of microalbuminuria tests in such a short period is a testament to our long-standing commitment to advancing optimum therapeutic outcomes for hypertensive patients in India,” stated Dilip Singh Rathore, President, India Business, JB Pharma. “Having conducted more than 5 lakh screenings over the past 8 years, this recent accomplishment demonstrates our intensified focus on proactive hypertension management and kidney protection.”

Out of the total individuals screened by JB Pharma across India, around 18% were identified as hypertensive. Among these hypertensive patients, approximately 67% (or two-thirds) showed early signs of potential kidney damage.

This record-breaking effort highlights the urgent need for early intervention, as Vikas Khare Executive Vice President – Chronic Cluster, India Business, JB Pharma explained: “Microalbuminuria testing is vital for identifying early signs of kidney stress in hypertensive patients, often before chronic kidney disease develops. Since hypertension can severely affect kidney health, detecting microalbuminuria early allows for timely action to protect kidney function and improve patient outcomes. With this record achievement, we, at JB Pharma continue to advance on our promise of being Good People for Good Health.”

Recognizing that hypertension and diabetes contribute to a significant 40-60% of kidney damage in India, JB Pharma is also actively working on promoting accurate blood pressure measurement and management through its long-standing campaign “BP Right Karo”. Under this initiative, JB Pharma also focuses on calibrating blood pressure devices across 10,000 clinics over the next 2-3 years, to ensure precise measurements, for informed healthcare decisions.

Through these impactful initiatives, JB Pharma continues to demonstrate its leadership in hypertension management and its dedication to improving the health outcomes of individuals at risk of hypertension-related kidney damage. The company remains committed to driving positive changes in cardiovascular care through data-driven interventions and community engagement.